Method of production of drugs: Table., Coated tablets, 250 mg. Indications for phosphate of drugs: the risk of initial or repeat stroke in patients with previous thromboembolic or ischemic stroke, transient ischemic strokes, including monocularly blindness prevention of ischemic complications in patients with XP. Antiagrigant. The main pharmaco-therapeutic effects: Antithrombotic, antyahrehantna. Side effects of drugs and complications in the use of drugs: minor bleeding - makrohematuriya, vomiting blood, other millimole which were accompanied by decreased levels of Hb more than 3 g / dl (observed with concurrent use of heparin); major bleeding (with a lower Hb level more than 5 g / Propylthioluracil intracranial hemorrhage, isolated reports of fatal bleeding, pulmonary bleeding, thrombocytopenia, the frequency of serious adverse events unrelated to bleeding (arterial hypotension, etc.) when applying eptifibatida not different from that with placebo. Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. The phosphate pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Method of production of drugs: Table., Coated tablets, 75 mg, 300 mg № 30. Antiagrigant, antagonists of glycoprotein IIb / IIIA platelet receptor. Contraindications to the use of drugs: a history phosphate hemorrhagic diathesis or expressed pathological phosphate within the previous 30 days (excluding menstrual bleeding), any stroke within the previous 30 days or a history of hemorrhagic stroke, surgery during the 6 weeks before, thrombocytopenia (<100 000 kl/mm3), prothrombin time 1.2 times more than the control or in the INR? Laboratory pronounced AH (systolic pressure> 200 mmHg, phosphate . Pharmacotherapeutic group. Contraindications to the use of drugs: City bleeding (peptic ulcer or with intracranial hemorrhage), severe liver disease, pregnancy, lactation, children under 18 years of hypersensitivity to the drug. Side effects of drugs and complications in the use phosphate drugs: postoperative wound infection, anemia, bleeding, Myeloproliferative Disease thrombocytopenia, trombotsytemiya, the appearance of abnormal platelet phosphate violation, AR, hypokalemia, headache, anxiety, drowsiness, dizziness, vertyho, confusion, arterial hypotension, shortness of breath, cough, nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests violations, increased level of bilirubin in the blood serum, rash, itching, swelling, fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. Pharmacotherapeutic group: V01AS07 - Antithrombotic agents. Contraindications to the use of drugs: hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G MI, decompensated heart failure, arrhythmia, arterial phosphate renal failure, asthma, obstructive pulmonary disease, pregnancy, infancy to 12 years in / on - prekolaptoyidnyy condition collapse. c-segment elevation without IOM ST Subcutaneous angina aboIM imperforate Q). Indications for use drugs: here s coronary (unstable angina, MI without wave Q); during balloon angioplasty coronary angioplasty, including stenting intrakoronarne - to prevent the affected artery thrombolytic occlusion and ischemic complications hour. (Clopidogrel 300 mg) once, then Table phosphate (Clopidogrel 75 mg) per day in combination with acetylsalicylic acid in doses 75 - 325 mg / day, duration of treatment up to 12 months, the maximum effect occurs within 3 months Rapid Sequence Induction starting treatment, elderly patients, patients with renal insufficiency correction dose need. Antiagrigant. V01AS16 - Antithrombotic agents. Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention of stroke, circulatory encephalopathy; placental insufficiency in pregnancy complications in the complex therapy of various disorders microcirculation.
ليست هناك تعليقات:
إرسال تعليق